Linaclotide
ApprovedCompleted 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Irritable Bowel Syndrome With Constipation
Conditions
Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation
Trial Timeline
Nov 1, 2015 → Feb 5, 2018
NCT ID
NCT02590432About Linaclotide
Linaclotide is a approved stage product being developed by Ironwood Pharmaceuticals for Irritable Bowel Syndrome With Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT02590432. Target conditions include Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02590432 | Approved | Completed |
| NCT00765999 | Phase 3 | Completed |
| NCT00730171 | Phase 3 | Completed |
Competing Products
20 competing products in Irritable Bowel Syndrome With Constipation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| linaclotide + placebo | Astellas Pharma | Phase 2 | 52 |
| YM060 + Placebo | Astellas Pharma | Phase 3 | 77 |
| Ramosetron + Placebo | Astellas Pharma | Approved | 85 |
| Ramosetron + Placebo | Astellas Pharma | Approved | 85 |
| YM060 | Astellas Pharma | Phase 3 | 77 |
| YM060 + placebo | Astellas Pharma | Phase 2 | 52 |
| YM060 | Astellas Pharma | Phase 3 | 77 |
| linaclotide + Placebo | Astellas Pharma | Phase 3 | 77 |
| Ramosetron | Astellas Pharma | Pre-clinical | 23 |
| YM060 | Astellas Pharma | Phase 2 | 52 |
| ONO-2952 + Placebo comparator | Ono Pharmaceutical | Phase 2 | 52 |
| ONO-2952 + ONO-2952 Matching Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| duloxetine | Eli Lilly | Approved | 85 |
| Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers) | AbbVie | Phase 3 | 77 |
| 25mg Eluxadoline + 100mg Eluxadoline | AbbVie | Phase 3 | 77 |
| Eluxadoline + Placebo | AbbVie | Phase 2 | 52 |
| Placebo + Linaclotide | AstraZeneca | Phase 3 | 77 |
| Tegaserod | Novartis | Pre-clinical | 23 |
| DNK333 | Novartis | Phase 2 | 52 |
| SMS995 + Placebo | Novartis | Phase 1 | 33 |